Menu
Home
Log in / Register
 
Home arrow Health arrow Cognitive impairment and dementia in Parkinson disease
Source

Conclusions

The point prevalence of PD-D is close to 30% and the incidence rate is increased four to six times compared with people without PD. In addition, MCI occurs in 20-25% of PD patients without dementia. The cumulative prevalence is very high—at least 75% of PD patients who survive for more than 10 years will develop dementia. The time from onset of PD to dementia varies considerably. The most established risk factors are old age, severity of motor symptoms, in particular PIGD, and the presence of MCI, VH, and RBD.

References

  • 1. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708-13.
  • 2. Cummings JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24-36.
  • 3. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20: 1255-63.
  • 4. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004; 19: 1043-9.
  • 5. Mekawichai CL. The prevalence and the associated factors of dementia in patients with Parkinson’s disease at Maharat Nakhon Ratchasima hospital. J Med Assoc Thai 2013; 96: 440-5.
  • 6. Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson’s disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing 2005; 34: 268-73.
  • 7. De Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62: 1265-9.
  • 8. Riedel O, Schneider C, Klotsche J, et al. The prevalence of Parkinson’s disease, associated dementia, and depression in Dresden. Fortschr Neurol Psychiatry 2013; 81: 81-7.
  • 9. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258-64.
  • 10. Aarsland D, Andersen K, Larsen J, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001; 56: 730-6.
  • 11. Marder K, Tang MX, Alfaro B, et al. Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia. Neurology 1999; 52: 719-24.
  • 12. Yip AG, Brayne C, Matthews FE. Risk factors for incident dementia in England and Wales: the Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing 2006; 35: 154-60.
  • 13. Williams-Gray CH, Foltynie T, Brayne C, et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007; 130: 1787-98.
  • 14. Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. J Am Med Assoc Neurol 2013; 70: 580-6.
  • 15. Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. J Am Med Assoc Neurol 2013; 70: 1396-402.
  • 16. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson’s disease. Neurology 1990; 40: 1513-17.
  • 17. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 1995; 52: 695-701.
  • 18. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000; 54: 1596-602.
  • 19. Hobson P, Gallacher J, Meara J. Cross-sectional survey of Parkinson’s disease and parkinsonism in a rural area of the United Kingdom. Mov Disord 2005; 20: 995-8.
  • 20. Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
  • 21. Hely MA, Morris JGL, Reid WGJ, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa- responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-9.
  • 22. Buter TC, Van Den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017-22.
  • 23. Perez F, Helmer C, Foubert-Samier A, et al. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement 2012; 8: 463-9.
  • 24. Reid WGJ, Hely MA, Morris JG, et al. A longitudinal of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996; 3: 327-33.
  • 25. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
  • 26. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254: 38-45.
  • 27. Halliday G, Hely M, Reid WGJ, et al. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008; 115: 409-15.
  • 28. Wada K, Nakashima K. Mild cognitive impairment in Parkinson’s disease. Brain Nerve 2012; 64: 1365-75.
  • 29. Janvin CC, Larsen JP, Aarsland D, et al. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 2006; 21: 1343-9.
  • 30. Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain 2012; 135: 161-9.
  • 31. Marion MH, Qurashi M, Marshall G, et al. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J. Neurol 2008; 255: 192-6.
  • 32. Haugarvoll K, Aarsland D, Wentzel-Larsen T, et al. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol Scand 2005; 112: 386-90.
  • 33. Rektor I, Goldemund D, Sheardova K, et al. Vascular pathology in patients with idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2009; 15: 24-9.
  • 34. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009; 24: 1437-44.
  • 35. Slawek J, Wieczorek D, Derejko M, et al. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson’s disease. Mov Disord 2008; 42: 505-12.
  • 36. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 2006; 21: 1123-30.
  • 37. Burn DJ, Rowan EN, Allan LM, et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-9.
  • 38. Tremblay C, Achim AM, Macoir J, et al. The heterogeneity of cognitive symptoms in Parkinson’s disease: a meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84: 1265-72.
  • 39. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-56.
  • 40. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-9.
  • 41. Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-6.
  • 42. Elgh E, Domellof M, Linder J, et al. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol 2009; 16: 1278-84.
  • 43. Foltynie T, Brayne CEG, Robbins TW, et al. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
  • 44. Muslimovic D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-45.
  • 45. Broeders M, de Bie RM, Velseboer DC, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013; 81: 346-52.
  • 46. Bronnick K, Emre M, Lane R, et al. Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 1064-8.
  • 47. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
  • 48. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79: 652-5.
  • 49. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906-11.
  • 50. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
  • 51. Perry AF, Kerwin EK, Perry J, et al. Visual hallucinations and the cholinergic system in dementia. J Neurol Neurosurg Psychiatry 1990; 53: 88.
  • 52. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003; 60: 1756-61.
  • 53. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson’s disease. Ann Neurol 2009; 66: 39-47.
  • 54. Vendette M, Gagnon JF, Decary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007; 69: 1843-9.
  • 55. Yoritaka A, Ohizumi H, Tanaka S, et al. Parkinson’s disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 2009; 61: 164-70.
  • 56. Dugger BN, Boeve BF, Murray ME, et al. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord 2012; 27: 72-8.
  • 57. Eisensehr I, Lindeiner H, Jager M, et al. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson’s disease: is there a need for polysomnography? J Neurol Sci 2001; 186: 7-11.
  • 58. Scaglione C, Vignatelli L, Plazzi G, et al. REM sleep behaviour disorder in Parkinson’s disease: a questionnaire-based study. Neurol Sci 2005; 25: 316-21.
  • 59. Derejko M, Slawek J, Wieczorek D, et al. Regional cerebral blood flow in Parkinson’s disease as an indicator of cognitive impairment. Neurol Neurochir Pol 2008; 24: 505-12.
  • 60. Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol 2013; 12: 597-608.
  • 61. Shin J, Choi S, Lee JE, et al. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson’s disease patients according to cognitive status. J Neurol Neurosurg Psychiatry 2012; 83: 315-21.
  • 62. Kurz MW, Schlitter AM, Larsen JP, et al. Familial occurrence of dementia and parkinsonism: a systematic review. Dement Geriatr Cogn Disord 2006; 22: 288-95.
  • 63. Rocca WA, Bower JH, Ahlskog JE, et al. Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol 2007; 64: 1458-64.
  • 64. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68: 916-22.
  • 65. Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008; 63: 743-50.
  • 66. Johansen KK, White LR, Sando SB, et al. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 2010; 16: 307-15.
  • 67. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004; 364: 1167-9.
  • 68. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174-9.
  • 69. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nature Genet 1998; 18: 106-8.
  • 70. Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66: 578-83.
  • 71. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009; 132: 1783-94.
  • 72. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009; 361: 1651-61.
  • 73. Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson’s disease. Parkinsonism Relat Disord 2009; 15: 721-7.
  • 74. Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 2012; 79: 1027-32.
  • 75. Hentati E, Nabli F, Trabelsi M, et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 243-6.
  • 76. Jones EL, Aarsland D, Londos E, et al. A pilot study examining associations between DYRK1A and a-synuclein dementias. Neurodegener Dis 2012; 10: 229-31.
  • 77. Bialecka M, Kurzawski M, Roszmann A, et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson’s disease. Neurosci Lett 2014; 561: 86-90.
  • 78. Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 2007; 414: 141-4.
  • 79. Huang X, Chen P, Kaufer DI, et al. Apolipoprotein E and dementia in Parkinson disease: a metaanalysis. Arch Neurol 2006; 63: 189-93.
  • 80. Jasinska-Myga B, Opala G, Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007; 64: 261-5.
  • 81. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 2007; 62: 145-53.
  • 82. Healy DG, Abou-Sleiman PM, Lees AJ, et al. Tau gene and Parkinson’s disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry 2004; 75: 962-5.
  • 83. Weisskopf MG, Grodstein F, Ascherio A. Smoking and cognitive function in Parkinson’s disease. Mov Disord 2007; 22: 660-5.
  • 84. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007; 78: 641-3.
  • 85. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-8.
  • 86. Mattila PM, Roytta M, Lonnberg P, et al. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol 2001; 102:
  • 160-6.
  • 87. Grujic Z. Cognitive disturbances in Parkinson’s disease. Dis Mon 2007; 53: 302-8.
  • 88. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.
  • 89. Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry 2010; 81: 160-5.
  • 90. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235-8.
  • 91. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson’s disease. Mov Disord 2006; 21: 1375-9.
  • 92. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease. Neurosci Lett 2006; 404: 56-60.
  • 93. O’Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-8.
 
Source
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
 
Subjects
Accounting
Business & Finance
Communication
Computer Science
Economics
Education
Engineering
Environment
Geography
Health
History
Language & Literature
Law
Management
Marketing
Mathematics
Political science
Philosophy
Psychology
Religion
Sociology
Travel